Evidence map›Paper›PMID 39980610›Full record

ArticleRespiratory medicine case reports2025

Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report.

Mohamad Hadhud, Johnathan Arnon, Anat Hershko-Moshe, Adi Hollander, Noa Hurvitz-Lehmann, Assaf Potruch, Henny Azmanov, Rottem Kuint, Nurith Hiller, Elie Picard and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer Consortium.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mohamad HadhudPediatric Pulmonary Unit and Cystic Fibrosis Center, Hadassah Medical Center, Jerusalem, Israel.
Johnathan ArnonFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Anat Hershko-MosheFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Adi HollanderFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Noa Hurvitz-LehmannFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Assaf PotruchFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Henny AzmanovFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Rottem KuintFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Nurith HillerFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Elie PicardPediatric Pulmonary Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
Naama Sebbag-SznajderHadassah Organoid Center, Hadassah Medical Center, Jerusalem, Israel.
Shira LeebhoffHadassah Organoid Center, Hadassah Medical Center, Jerusalem, Israel.
Michael WilschanskiFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Myriam GrunewaldFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Liron Birimberg-SchwartzFaculty of Medicine, Hebrew University of Jerusalem, Israel.
Malena Cohen-CymberknohPediatric Pulmonary Unit and Cystic Fibrosis Center, Hadassah Medical Center, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is uncommon among people with cystic fibrosis (pwCF). We describe the case of a 35-year-old man with mild, stable CF disease who presented with severe respiratory distress, systemic symptoms, elevated liver enzymes and hypereosinophilia along with a lung mass and pleural effusion. The patient was subsequently diagnosed with non-small cell lung carcinoma (NSCLC), featuring anaplastic lymphoma kinase (ALK) translocation. Following treatment with a targeted tyrosine kinase inhibitor (TKI) there was a rapid tumor regression, however, his dyspnea and hypoxemia subsequently worsened. A trial of Elexacaftor/Tezacaftor/Ivacaftor (ETI) led to significant clinical improvement and enhanced pulmonary function.

Indexed as

ALK translocationCystic fibrosisElexacaftor/tezacaftor/ivacaftorIntestinal organoidsNon-small cell lung cancer

Identifiers

PMID39980610
PMCPMC11841201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.